Safety and Efficacy of MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

Trial Profile

Safety and Efficacy of MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2014

At a glance

  • Drugs Squalamine (Primary) ; Verteporfin
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genaera Corporation
  • Most Recent Events

    • 02 Apr 2014 New trial record
    • 27 Nov 2007 Status changed from completed to discontinued, as reported by ClinicalTrials.gov.
    • 18 Jul 2005 Results presented at the 23rd Annual Meeting of the American Society of Retina Specialists (ASRS), according to a Genaera Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top